Drug Profile
Opebacan ophthalmic
Alternative Names: BPI 21 ophthalmic; I-PREX; rBPI 21 ophthalmic; Recombinant bactericidal permeability increasing protein 21 ophthalmicLatest Information Update: 03 Aug 2005
Price :
$50
*
At a glance
- Originator XOMA
- Class Antibacterials; Recombinant proteins
- Mechanism of Action Cell membrane permeability enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Ocular inflammation; Ophthalmic infections
Most Recent Events
- 15 Jul 2005 XOMA has terminated its license agreement with Zephyr Sciences for ophthalmic opebacan
- 10 Nov 2004 Opebacan ophthalmic has been licensed to Zephyr Sciences worldwide
- 24 Nov 2000 Allergan has returned all rights to I-PREX™ to XOMA